Xcout Intel
Outer Biosciences, LLC
Outer Biosciences specializes in developing breakthrough bioactives for skin health by discovering novel components from underexplored natural sources using an advanced ex vivo platform. Headquartered in Malden, the company aims to improve human health and skin care through innovative biological research.
Subscribe to see Outer Biosciences, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Outer Biosciences, LLC at a glance
Outer Biosciences, LLC is a biotechnology company headquartered in United States. It has raised at least $27.3M across the 2 funding rounds on record. Its most recent funding round raised $23.3M in June 2024.
Outer Biosciences, LLC funding rounds
At least $27.3M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $23.3M | — | |
| SEC Form D filing | $4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Outer Biosciences, LLC news
- FundingPrivate placement (Form D)
Outer Biosciences, LLC competitors
A few of Outer Biosciences, LLC's closest competitors — see the full list of competitors and alternatives →
Superluminal Medicines is a generative biology and chemistry company headquartered in Boston, Massachusetts, focused on drug discovery and development.
Enveda Biosciences (Enveda Therapeutics Inc.) is a biotechnology research company headquartered in Boulder, Colorado. The company leverages artificial intelligence to discover novel therapeutics and chemical compounds derived from natural sources.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Orionis Biosciences is a biotechnology research company with its US headquarters located in Waltham, Massachusetts, specializing in innovative life sciences and drug discovery services.
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Get Outer Biosciences, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Outer Biosciences, LLC? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Outer Biosciences, LLC in Xcout Intel
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access